<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01332526</url>
  </required_header>
  <id_info>
    <org_study_id>FFT Bydgoszcz</org_study_id>
    <nct_id>NCT01332526</nct_id>
  </id_info>
  <brief_title>FFT, Inflammation, Lipid Metabolism, Blood Pressure and Organ Damage in Patients With Obesity, Chronic Kidney Disease (CKD).</brief_title>
  <official_title>The Oral Fructose Load Test and Inflammation, Lipid Metabolism, Blood Pressure and Organ Damage in Patients With Obesity, Chronic Kidney Disease With Comparison With Healthy Controls.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Collegium Medicum w Bydgoszczy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Collegium Medicum w Bydgoszczy</source>
  <brief_summary>
    <textblock>
      Fructose intake from added sugars has increased dramatically over the last century and has&#xD;
      recently been implicated as potential contributor to metabolic syndrome, obesity,&#xD;
      hypertension, inflammation and kidney disease. Fructose differs from the other sugars&#xD;
      because, uric acid is generated during its metabolism. Serum uric acid levels have been found&#xD;
      to correlate with the intake of fructose and added sugars. In turn, an elevated serum uric&#xD;
      acid has also been shown to be associated with increased risk for cardiovascular and&#xD;
      metabolic diseases. On the other hand complexity of fructose metabolism in each individuals&#xD;
      results of the various magnitude of hyperuricemia induced by fructose intake. The magnitude&#xD;
      of uric acid production in each patient may reflect individual predisposition to endogenous&#xD;
      urate production in a face of relatively normal fasting uric acid concentration. Therefore&#xD;
      the oral fructose tolerance test might reveal an occult purine disturbances which plays&#xD;
      casual role in either metabolic disturbances or organ damage.&#xD;
&#xD;
      The aim of this study is to see whether is a relationship between fructose induced&#xD;
      hyperuricemia and metabolic disturbances , inflammatory state and organ damage in obese and&#xD;
      various stages CKD patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be performed in two experimental groups. Proposed study groups Study I&#xD;
      Patients with BMI&gt; 30 and metabolic syndrome. Patient with BMI&gt; 30 without metabolic&#xD;
      syndrome. Normal healthy controls. Study II Patients with CKD stage III and uric acid &lt; 7&#xD;
      mg/dl Patients with CKD stage III and uric acid &gt; 7 mg/dl Patient with asymptomatic&#xD;
      hyperuricemia and eGFR &gt; 90 ml/min/1.73 m2, , uric acid &gt; 7 mg/dl Hemodialysis patients&#xD;
&#xD;
      Characteristics of the particular patients group- including criteria:&#xD;
&#xD;
      10- 15 participants in each subset of each group age 18-65 y. Gender: females and males in&#xD;
      equal proportion. Group I Patients with BMI&gt; 30 and metabolic syndrome ( ATP III). Patient&#xD;
      with BMI&gt; 30 without metabolic syndrome. Normal healthy control- healthy persons( without&#xD;
      renal disease, cardiovascular diseases, diabetes mellitus, BMI &lt; 25;normotensives ).&#xD;
&#xD;
      Group II Patients with CKD stage III (GFR 30-59 ml/min/1,73 m2) and uric acid &lt; 7 mg/dl.&#xD;
&#xD;
        -  without diabetes mellitus proteinuria &lt; 3,5 g/24 h without immunosuppressive agents,&#xD;
           ACEi, ARB, allopurinol treatment well controlled hypertension ( &lt; 140/90 mmHg) Patients&#xD;
           with CKD stage III(GFR 30-59 ml/min/1,73 m2) and uric acid &gt; 7 mg/dl&#xD;
&#xD;
        -  without diabetes mellitus proteinuria &lt; 3,5 g/24 h without immunosuppressive agents,&#xD;
           ACEi, ARB, allopurinol treatment well controlled hypertension ( &lt; 140/90 mmHg)&#xD;
&#xD;
      Patient with asymptomatic hyperuricemia, uric acid &gt; 7 mg/dl with normal renal function&#xD;
      Hemodialysis patients.&#xD;
&#xD;
        -  CKD: nondiabetic nephropathy&#xD;
&#xD;
        -  duration hemodialysis 3-48 months&#xD;
&#xD;
        -  Hb-11-13 g/dl&#xD;
&#xD;
        -  well controlled hypertension ( &lt; 140/90 mmHg)&#xD;
&#xD;
        -  without ACEi, ARB, allopurinol treatment&#xD;
&#xD;
        -  residual diuresis will be estimated for last 48 hours-between mid and next dialysis&#xD;
           Method of investigation All patients and controls ( but hemodialysis) will present after&#xD;
           overnight fast. Baseline tests include 24 hr urine collection for: sodium, calcium,&#xD;
           phosphorus, creatinine, uric acid, NAG, albumin will be carry out and the same morning&#xD;
           fasting sample of blood for: creatinine, cystatin C , uric acid, sodium, glucose,&#xD;
           insulin, triglycerides, HDL and LDL cholesterol, calcium, phosphorus, hsCRP. BP will be&#xD;
           determined as the mean of three readings taken 5 min apart while sitting. Next in all&#xD;
           patients and controls fructose tolerance test will be performed. The test consists of&#xD;
           giving 1 gram/kg b.w. of fructose p.o. with blood collection at 0,30,60 and 120 min&#xD;
           afterward for serum uric acid determination and uric acid area under the curve will be&#xD;
           calculated. The calculated area under curve is the measure of occult uric acid&#xD;
           disturbance when compared to controls.&#xD;
&#xD;
      Day before the urine collection the ABPM , BMI, IM (intima media ratio) , renal duplex&#xD;
      ultrasound (RI) will be done&#xD;
&#xD;
      Measure BMI, waist circumference&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Obesity</condition>
  <condition>Chronic Kidney Disease</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Patients with BMI&gt; 30 and metabolic syndrome ( ATP III).</arm_group_label>
    <description>Patients with BMI&gt; 30 and metabolic syndrome ( ATP III).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient with BMI&gt; 30 without metabolic syndrome.</arm_group_label>
    <description>Patient with BMI&gt; 30 without metabolic syndrome.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal healthy control</arm_group_label>
    <description>healthy persons( without renal disease, cardiovascular diseases, diabetes mellitus, BMI &lt; 25;normotensives ).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with CKD stage III and uric acid &lt; 7 mg/dl</arm_group_label>
    <description>Patients with CKD stage III (GFR 30-59 ml/min/1,73 m2) and uric acid &lt; 7 mg/dl.&#xD;
without diabetes mellitus proteinuria &lt; 3,5 g/24 h without immunosuppressives agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( &lt; 140/90 mmHg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with CKD stage III and uric acid &gt; 7 mg/dl</arm_group_label>
    <description>Patients with CKD stage III(GFR 30-59 ml/min/1,73 m2) and uric acid &gt; 7 mg/dl&#xD;
without diabetes mellitus proteinuria &lt; 3,5 g/24 h without immunosuppressive agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( &lt; 140/90 mmHg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient with asymptomatic hyperuricemia</arm_group_label>
    <description>Patient with asymptomatic hyperuricemia, uric acid &gt; 7 mg/dl with normal renal function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hemodialysis patients</arm_group_label>
    <description>Patient with asymptomatic hyperuricemia, uric acid &gt; 7 mg/dl with normal renal function Hemodialysis patients.&#xD;
CKD: nondiabetic nephropathy&#xD;
duration hemodialysis 3-48 months&#xD;
Hb-11-13 g/dl&#xD;
well controlled hypertension ( &lt; 140/90 mmHg)&#xD;
without ACEi, ARB, allopurinol treatment&#xD;
residual diuresis will be estimated for last 48 hours-between mid and next dialysis</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Study I Patients with BMI&gt; 30 and metabolic syndrome. Patient with BMI&gt; 30 without&#xD;
        metabolic syndrome. Normal healthy controls. Study II Patients with CKD stage III and uric&#xD;
        acid &lt; 7 mg/dl Patients with CKD stage III and uric acid &gt; 7 mg/dl Patient with&#xD;
        asymptomatic hiperuricemia and eGFR &gt; 90 ml/min/1.73 m2, , uric acid &gt; 7 mg/dl Hemodialysis&#xD;
        patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Group I Patients with BMI&gt; 30 and metabolic syndrome ( ATP III). Patient with BMI&gt; 30&#xD;
        without metabolic syndrome. Normal healthy control- healthy persons( without renal disease,&#xD;
        cardiovascular diseases, diabetes mellitus, BMI &lt; 25;normotensives ).&#xD;
&#xD;
        Group II Patients with CKD stage III (GFR 30-59 ml/min/1,73 m2) and uric acid &lt; 7 mg/dl.&#xD;
&#xD;
          -  without diabetes mellitus proteinuria &lt; 3,5 g/24 h without immunosuppressives agents,&#xD;
             ACEi, ARB, allopurinol treatment well controlled hypertension ( &lt; 140/90 mmHg)&#xD;
             Patients with CKD stage III(GFR 30-59 ml/min/1,73 m2) and uric acid &gt; 7 mg/dl&#xD;
&#xD;
          -  without diabetes mellitus proteinuria &lt; 3,5 g/24 h without immunosuppressive agents,&#xD;
             ACEi, ARB, allopurinol treatment well controlled hypertension ( &lt; 140/90 mmHg)&#xD;
&#xD;
        Patient with asymptomatic hyperuricemia, uric acid &gt; 7 mg/dl with normal renal function&#xD;
        Hemodialysis patients.&#xD;
&#xD;
          -  CKD: nondiabetic nephropathy&#xD;
&#xD;
          -  duration hemodialysis 3-48 months&#xD;
&#xD;
          -  Hb-11-13 g/dl&#xD;
&#xD;
          -  well controlled hypertension ( &lt; 140/90 mmHg)&#xD;
&#xD;
          -  without ACEi, ARB, allopurinol treatment&#xD;
&#xD;
          -  residual diuresis will be estimated for last 48 hours-between mid and next dialysis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  immunosuppressive agents, ACEi, ARB, allopurinol treatment&#xD;
&#xD;
          -  diabetes mellitus&#xD;
&#xD;
          -  not well controlled hypertension ( &gt; 140/90 mmHg)&#xD;
&#xD;
          -  proteinuria &gt; 3,5 g/24 h&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacek JM Manitius</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Nephrology, Hypertension and Internal Diseases Nicolaus Copernicus University in Torun Poland Collegium Medicum in Bydgoszcz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacek JM Manitius</last_name>
    <phone>+48525854030</phone>
    <email>nerka@nerkacpro.pl</email>
  </overall_contact>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>March 31, 2011</study_first_submitted>
  <study_first_submitted_qc>April 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2011</study_first_posted>
  <last_update_submitted>April 15, 2011</last_update_submitted>
  <last_update_submitted_qc>April 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>Richard Johnson M.D.</name_title>
    <organization>Chief, Division of Renal Diseases and Hypertension</organization>
  </responsible_party>
  <keyword>FFT</keyword>
  <keyword>inflammation</keyword>
  <keyword>lipid metabolism</keyword>
  <keyword>hyperuricemia</keyword>
  <keyword>Agents Affecting Uric Acid Metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

